search
Back to results

Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.

Primary Purpose

Hepatic Encephalopathy

Status
Completed
Phase
Phase 4
Locations
Mexico
Study Type
Interventional
Intervention
L-ornithine-L-aspartate
Lactose
Sponsored by
Centro Regional para el Estudio de las Enfermedades Digestivas
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Hepatic Encephalopathy focused on measuring Encephalopathy, Cirrhosis

Eligibility Criteria

18 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients with cirrhosis of any etiology, diagnosed by ultrasound,clinical and / or histologic criteria
  • Patients over 18 years and under 75
  • Patients with hepatic encephalopathy grade 3-4 according to the criteria of West Haven
  • Patients with hyperammonemia >10 µmol/l

Exclusion Criteria:

  • Evidence of neurological or psychiatric illness
  • Use of drugs affecting the central nervous system
  • Withdrawal Syndrome
  • Anorectal disease that interferes with the administration of enemas

Sites / Locations

  • Hospital Universitario "José Eleuterio González"

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Intravenous infusion of L- Ornithine L- Aspartate

Lactose enemas

Arm Description

a) 20 g L-ornithine-L-aspartate

b) 20% Lactose enemas

Outcomes

Primary Outcome Measures

Improvement of at least one grade in mental state based on the West Haven Criteria
Improvement was assessed at 0, 24, 48 and 72 hours. The mental state was scored from trivial lack of awareness to deep coma from grade 1 to grade 4.

Secondary Outcome Measures

Improvement of at least one grade in mental state assessed by the Glasgow Coma Scale
Improvement was assessed at 0, 24, 48 and 72 hours. The Glasgow Coma Scale assesses three aspects of responsiveness: eye-opening, motor, and verbal responses. The eye-opening was quantified from 1 to 4 points, the motor response from 1 to 6 points and the verbal response from 1 to 5 points.
Improvement of at least one grade in mental state assessed by the Clinical Hepatic Encephalopathy Staging Scale (CHESS)
Improvement was assessed at 0, 24, 48 and 72 hours. The CHESS scale has 9 dichotomous questions that assess mental state, intellectual function, behavior, verbal and motor response and orientation. It was quantified from 0 to 9 points.
Improvement of asterixis grade
Improvement was assessed at 0, 24, 48 and 72 hours. Asterixis was graded as follows: Grade 0 = without flapping motion, Grade 1 ≤ 5 flaps per minute, Grade 2 = 6 to 10 flaps per minute, Grade 3 = 11 to 20 flaps per minute and Grade 4, continuous flap or patient in coma unable to maintain wrist dorsiflexion. Asterixis grade was evaluated at 0. 24, 48 and 72 hours.
Improvement in electroencephalographic tracing grade
Improvement was assessed at 0 and 72 hours. EEG tracing was graduated from 0 to 4: Grade 0 = normal alpha rhythm, Grade 1 =7 to 8 cycles per second, Grade 2= 5 to 6 cycles per second, Grade 3 = 3 to 4.5 cycles per second and Grade 4 < than 3 cycles per second or delta rhythm. EEG was assessed at 0 and 72 hours.
Improvement in serum ammonia
Ammonia determination was performed at 0, 24, 48 and 72 hours.
Improvement in Number connection tests
The mental state of the patients included in the study did not allow them to perform the number connection test, therefore, they were all assigned to the worst score (Grade 4)
Improvement in Portosystemic Encephalopathy Index.
Improvement was assessed at 0 and 72 hours. The PSE Index was calculated by multiplying the grade of mental state by a factor of 3; and the grades of asterixis, number connection tests, serum ammonia and EEG were multiplied times a factor of 1. The results were divided by the maximal possible PSE sum.

Full Information

First Posted
December 31, 2009
Last Updated
May 6, 2021
Sponsor
Centro Regional para el Estudio de las Enfermedades Digestivas
Collaborators
MERZ PHARMA
search

1. Study Identification

Unique Protocol Identification Number
NCT01041755
Brief Title
Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.
Official Title
The Infusion of L-Ornithine L-aspart is as Effective as Nonabsorbable Disaccharides in the Management of Acute Hepatic Encephalopathy.
Study Type
Interventional

2. Study Status

Record Verification Date
May 2021
Overall Recruitment Status
Completed
Study Start Date
November 2009 (Actual)
Primary Completion Date
June 2011 (Actual)
Study Completion Date
June 2011 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Centro Regional para el Estudio de las Enfermedades Digestivas
Collaborators
MERZ PHARMA

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Hepatic encephalopathy is caused by the effects on the brain of substances that under normal circumstances are efficiently metabolized in the liver. The hyperammonemia is the main factor responsible for the development of hepatic encephalopathy. In patients with cirrhosis, the reduction in hepatocellular function and generation of portosystemic shunts contribute to increase serum ammonium. The current therapeutic approaches, are aimed at reducing blood ammonium levels. Administration of the non-absorbable disaccharides, have become standard treatment of hepatic encephalopathy.There are no adequate clinical trials comparing the efficacy of L-Ornithine-L-Aspartate (LOLA) infusion against lactose enemas in the treatment of acute hepatic encephalopathy.
Detailed Description
The main impact of hepatic encephalopathy in patients with cirrhosis is not related to costs, but its association with decreased survival and quality of life and should therefore clearly established the effectiveness of therapeutic interventions used in this disorder. At the end of the nineteenth century to the ammonium was identified as the main agent responsible for the development of the syndrome of hepatic encephalopathy. Since then, reduced nitrogen compounds from the intestine are considered the main therapeutic measure. On this conceptual base, nonabsorbable disaccharides are the first line therapy in hepatic encephalopathy. Current knowledge indicates that other organs such as muscle, brain and kidney are involved in the generation of ammonium, which has set the pace for the development of new treatments, able to act systemically in metabolism and elimination of ammonia . L-ornithine L-aspartate (LOLA) lowers ammonium concentrations in animal and humans models with hyperammonemia. There are no adequate clinical trials comparing the efficacy of LOLA infusion against lactose enemas in the treatment of acute hepatic encephalopathy.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Hepatic Encephalopathy
Keywords
Encephalopathy, Cirrhosis

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
30 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Intravenous infusion of L- Ornithine L- Aspartate
Arm Type
Experimental
Arm Description
a) 20 g L-ornithine-L-aspartate
Arm Title
Lactose enemas
Arm Type
Active Comparator
Arm Description
b) 20% Lactose enemas
Intervention Type
Drug
Intervention Name(s)
L-ornithine-L-aspartate
Other Intervention Name(s)
LOLA
Intervention Description
a) Intravenous infusion of 20 g L-ornithine-L-aspartate (4 ampules of 10 mL each) in 250 mL sodium chloride solution administered daily in 4 hours for 3 consecutive days, plus the placebo b) Water enemas, 1000 mL of water and given as retention enema every 12 hours for 3 consecutive days.
Intervention Type
Drug
Intervention Name(s)
Lactose
Intervention Description
a) 20% Lactose enemas, 200 g Lactose diluted with 700 mL of water and given as retention enema every 12 hours for 3 consecutive days, plus intravenous placebo b)250 mL sodium chloride solution, infusion for 4 hours for 3 consecutive days.
Primary Outcome Measure Information:
Title
Improvement of at least one grade in mental state based on the West Haven Criteria
Description
Improvement was assessed at 0, 24, 48 and 72 hours. The mental state was scored from trivial lack of awareness to deep coma from grade 1 to grade 4.
Time Frame
72 hours
Secondary Outcome Measure Information:
Title
Improvement of at least one grade in mental state assessed by the Glasgow Coma Scale
Description
Improvement was assessed at 0, 24, 48 and 72 hours. The Glasgow Coma Scale assesses three aspects of responsiveness: eye-opening, motor, and verbal responses. The eye-opening was quantified from 1 to 4 points, the motor response from 1 to 6 points and the verbal response from 1 to 5 points.
Time Frame
72 hours
Title
Improvement of at least one grade in mental state assessed by the Clinical Hepatic Encephalopathy Staging Scale (CHESS)
Description
Improvement was assessed at 0, 24, 48 and 72 hours. The CHESS scale has 9 dichotomous questions that assess mental state, intellectual function, behavior, verbal and motor response and orientation. It was quantified from 0 to 9 points.
Time Frame
72 hours
Title
Improvement of asterixis grade
Description
Improvement was assessed at 0, 24, 48 and 72 hours. Asterixis was graded as follows: Grade 0 = without flapping motion, Grade 1 ≤ 5 flaps per minute, Grade 2 = 6 to 10 flaps per minute, Grade 3 = 11 to 20 flaps per minute and Grade 4, continuous flap or patient in coma unable to maintain wrist dorsiflexion. Asterixis grade was evaluated at 0. 24, 48 and 72 hours.
Time Frame
72 hours
Title
Improvement in electroencephalographic tracing grade
Description
Improvement was assessed at 0 and 72 hours. EEG tracing was graduated from 0 to 4: Grade 0 = normal alpha rhythm, Grade 1 =7 to 8 cycles per second, Grade 2= 5 to 6 cycles per second, Grade 3 = 3 to 4.5 cycles per second and Grade 4 < than 3 cycles per second or delta rhythm. EEG was assessed at 0 and 72 hours.
Time Frame
72 hours
Title
Improvement in serum ammonia
Description
Ammonia determination was performed at 0, 24, 48 and 72 hours.
Time Frame
72 hours
Title
Improvement in Number connection tests
Description
The mental state of the patients included in the study did not allow them to perform the number connection test, therefore, they were all assigned to the worst score (Grade 4)
Time Frame
72 hours
Title
Improvement in Portosystemic Encephalopathy Index.
Description
Improvement was assessed at 0 and 72 hours. The PSE Index was calculated by multiplying the grade of mental state by a factor of 3; and the grades of asterixis, number connection tests, serum ammonia and EEG were multiplied times a factor of 1. The results were divided by the maximal possible PSE sum.
Time Frame
72 hours

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients with cirrhosis of any etiology, diagnosed by ultrasound,clinical and / or histologic criteria Patients over 18 years and under 75 Patients with hepatic encephalopathy grade 3-4 according to the criteria of West Haven Patients with hyperammonemia >10 µmol/l Exclusion Criteria: Evidence of neurological or psychiatric illness Use of drugs affecting the central nervous system Withdrawal Syndrome Anorectal disease that interferes with the administration of enemas
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Francisco J Bosques, MD, PhD
Organizational Affiliation
Centro Regional para el Estudio de las Enfermedades Digestivas
Official's Role
Study Director
First Name & Middle Initial & Last Name & Degree
Claudia Isabel Blanco Vela, MD
Organizational Affiliation
Hospital Juárez de México
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hospital Universitario "José Eleuterio González"
City
Monterrey
State/Province
Nuevo León
ZIP/Postal Code
64460
Country
Mexico

12. IPD Sharing Statement

Learn more about this trial

Efficacy of L-Ornithine L-Aspartate in Acute Hepatic Encephalopathy.

We'll reach out to this number within 24 hrs